|
Market Closed -
London S.E.
18:35:23 21/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 1,672.00 GBX | +1.21% |
|
+4.37% | +7.87% |
| 10-20 | Hikma Pharmaceuticals PLC - Special Call | |
| 09-24 | Hikma Pharmaceuticals appoints ViiV's Rebecca Hall as CFO | AN |
| Market Cap | 4.68B 4.17B 3.86B 3.49B 6.58B 442B 6.66B 46.29B 18.16B 232B 17.55B 17.19B 740B | P/E 2026 * |
12.2x | P/E 2027 * | 10.9x |
|---|---|---|---|---|---|
| Enterprise Value | 6.16B 5.49B 5.09B 4.6B 8.67B 582B 8.77B 60.97B 23.92B 306B 23.12B 22.64B 974B | EV / Sales 2026 * |
1.78x | EV / Sales 2027 * | 1.66x |
| Free-Float |
63.7% | Yield 2026 * |
3.86% | Yield 2027 * | 4.09% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| HIK | Delayed | |
CBOE
| HIK | Real-time | |
|
Mexican S.E.
| HIK N | End-of-day quote | |
|
Tradegate
| H5P | Real-time | |
|
OTC Markets
| HKMPF | Delayed | |
|
Boerse Muenchen
| H5P | Real-time | |
|
Deutsche Boerse AG
| H5P | Delayed | |
|
Börse Stuttgart
| H5P | Delayed |
Last Transcript: Hikma Pharmaceuticals PLC
| 1 day | +1.21% | ||
| 1 week | +4.37% | ||
| Current month | +3.34% | ||
| 1 month | +3.79% | ||
| 3 months | +8.57% | ||
| 6 months | +24.04% | ||
| Current year | +7.87% |
| 1 week | 1,615 |  | 1,682 |
| 1 month | 1,557 | | 1,682 |
| Current year | 1,187 | | 1,762 |
| 1 year | 1,187 | | 1,865 |
| 3 years | 1,187 | | 2,360 |
| 5 years | 1,174.5 | | 2,496 |
| 10 years | 814.2 | | 2,768 |
| Manager | Title | Age | Since |
|---|---|---|---|
Said Darwazah
CEO | Chief Executive Officer | 69 | 01/12/2025 |
Areb Kurdi
DFI | Director of Finance/CFO | - | 26/02/2026 |
Hill Julie
CMP | Compliance Officer | - | 01/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Douglas Hurt
BRD | Director/Board Member | 69 | 01/05/2020 |
Victoria Hull
CHM | Chairman | 63 | 26/02/2026 |
| Director/Board Member | 69 | 14/10/2005 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/1/26 A | Sell | Investor Relations Manager | -26,558 | 0.0124% | ||
| 6/1/26 A | Exercice | Director | 72,763 | 0.0339% | ||
| 6/1/26 A | Exercice | Director | 20,650 | 0.0096% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.21% | +4.37% | -6.23% | -13.81% | 4.68B | |
| -1.01% | +5.13% | +58.93% | +117.36% | 1,133B | |
| -0.61% | +1.52% | +34.34% | +68.48% | 621B | |
| -1.48% | +0.47% | +23.08% | +94.76% | 503B | |
| +0.54% | +5.69% | +39.60% | +64.02% | 379B | |
| +1.07% | +1.70% | +71.06% | +45.98% | 370B | |
| +0.30% | +3.44% | +21.35% | +49.62% | 292B | |
| -0.03% | +2.55% | +1.12% | +20.94% | 262B | |
| -0.14% | +2.87% | +45.56% | +57.22% | 237B | |
| -1.88% | +0.02% | +23.77% | +97.39% | 190B | |
| Average | +0.09% | +3.33% | +31.26% | +60.20% | 399.27B | |
| Weighted average by Cap. | +0.33% | +3.73% | +40.78% | +79.26% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.46B 3.08B 2.85B 2.58B 4.87B 326B 4.92B 34.21B 13.43B 172B 12.98B 12.71B 547B | 3.6B 3.21B 2.97B 2.69B 5.06B 340B 5.12B 35.61B 13.97B 179B 13.5B 13.22B 569B |
| Net income | 412M 367M 340M 308M 580M 38.9B 587M 4.08B 1.6B 20.45B 1.55B 1.51B 65.16B | 453M 404M 374M 339M 638M 42.79B 645M 4.49B 1.76B 22.49B 1.7B 1.67B 71.67B |
| Net Debt | 1.48B 1.32B 1.22B 1.11B 2.09B 140B 2.11B 14.68B 5.76B 73.64B 5.57B 5.45B 235B | 1.31B 1.17B 1.08B 978M 1.84B 124B 1.87B 12.96B 5.09B 65B 4.92B 4.81B 207B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/10/26 | GBX 1,672.00 | +1.21% | 464,563 |
| 20/10/26 | GBX 1,652.00 | -0.78% | 1,223,375 |
| 19/10/26 | GBX 1,665.00 | +0.18% | 346,184 |
| 16/10/26 | GBX 1,662.00 | +1.22% | 685,813 |
| 15/10/26 | GBX 1,642.00 | +2.50% | 416,233 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- HIK Stock
Select your edition
All financial news and data tailored to specific country editions
